Halozyme Therapeutics | HALO - Stock


Halozyme Therapeutics reported $155.47M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 31.57M 3.1M Mar/2026
Agios Pharmaceuticals USD 35.09M 2.17M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
Amarin USD 183.58M 12.32M Mar/2026
Amgen USD 6.19B 39M Mar/2026
Baxter International USD 2.32B 84M Mar/2026
Cara Therapeutics USD 900K 0 Mar/2025
Eli Lilly USD 14.53B 785M Mar/2026
Esperion Therapeutics USD 104.21M 915K Mar/2026
Halozyme Therapeutics USD 155.47M 21.01M Mar/2026
Intrexon USD 287K 68K Dec/2022
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
MannKind USD 49.17M 13.85M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Pfizer USD 10.67B 13M Mar/2026
Rigel Pharmaceuticals USD 13.3M 2.88M Sep/2025
United Therapeutics USD 178.3M 4.8M Mar/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025